Mansour AM, et al. - In eyes with macular diseases, researchers evaluated the 30-month outcome of treat and extend (TAE) intravitreal ziv-aflibercept therapy. In this prospective study, consecutive patients for various macular diseases were given intravitreal 0.05 mL ziv-aflibercept (1.25 mg) injections. Best-corrected visual acuity (BCVA) (logarithm of the minimum angle of resolution) and central macular thickness (CMT) on spectral domain optical coherence tomography were the outcome measures. Using the TAE regimen, an intravitreal ziv-aflibercept was effective for managing retinal disease through month 30.